Cue Biopharma (CUE)
(Delayed Data from NSDQ)
$0.67 USD
-0.06 (-7.94%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $0.68 +0.01 (1.18%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CUE 0.67 -0.06(-7.94%)
Will CUE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CUE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CUE
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
CUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
Other News for CUE
CUE forms Directional Movement Crossover Bearish on September 20
Cue Energy Releases 2025 Annual Report Highlighting Operational Focus
Cue Energy Resources Announces Virtual AGM for 2025
Is CUE likely to continue higher? Directional Movement Crossover Bullish shows up after climbing 1.08%
Cue Energy Updates Dividend Exchange Rate for NZD Conversion